Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:APVO

Aptevo Therapeutics 3/27/2026 Earnings Report

Aptevo Therapeutics logo
$4.75 -0.60 (-11.14%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aptevo Therapeutics EPS Results

Actual EPS
$118.23
Consensus EPS
-$8.10
Beat/Miss
Beat by +$126.33
One Year Ago EPS
N/A

Aptevo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptevo Therapeutics Announcement Details

Quarter
Date
3/27/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aptevo Therapeutics' next earnings date is estimated for Thursday, May 21, 2026, based on past reporting schedules.

Conference Call Resources

Aptevo Therapeutics Earnings Headlines

Aptevo Therapeutics (APVO) price target decreased by 99.72% to 21.42
March 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/aptevo-therapeutics-apvo-price-target-decreased-by-99-72-to-21-42/ar-AA1Zwnce
Aptevo Therapeutics: Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68047239-aptevo-therapeutics-aptevo-provides-state-of-the-business-report-and-2025-financial-results-200.htm
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
May 6 at 1:00 AM  |  Reagan Gold Group (Ad)
Aptevo Therapeutics: Aptevo to Participate in March 2026 Conferences
March 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67986832-aptevo-therapeutics-aptevo-to-participate-in-march-2026-conferences-200.htm
Roth MKM Keeps Their Buy Rating on Aptevo Therapeutics (APVO)
March 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/APVO/pressreleases/699518/roth-mkm-keeps-their-buy-rating-on-aptevo-therapeutics-apvo/
Aptevo Lists Lower on New Developments
March 10, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/22877/Aptevo-Lists-Lower-on-New-Developments
See More Aptevo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email.

About Aptevo Therapeutics

Aptevo Therapeutics (NASDAQ:APVO), Inc. is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life. Key product candidates in Aptevo’s pipeline include AFM13, a CD30/CD16A innate cell engager in development for CD30-positive lymphomas, and APVO436, a bispecific molecule targeting CD123 and CD3 for acute myeloid leukemia.

Aptevo Therapeutics conducts clinical studies across North America and Europe, partnering with academic centers and industry collaborators to advance its lead candidates through Phase 1/2 trials. The company’s approach emphasizes dual activation of innate and adaptive immune responses to achieve potent antitumor effects while reducing the risk of off-target toxicity.

Guided by a management team with extensive experience in biologic drug development and cell-based therapies, Aptevo continues to expand its pipeline and seek strategic partnerships to bring its immunotherapeutic candidates to patients with high-unmet medical needs.

View Aptevo Therapeutics Profile
Earnings Tools